Protein interaction creates a new treatment target for squamous cell carcinoma

Share this content:

A tumor-suppressing protein called alpha-catenin appears to stop the development of squamous cell carcinoma by keeping another protein—the cancer-causing Yap1—in check. 

Valeri Vasioukhin, PhD, of the University of Washington and Fred Hutchinson Cancer Research Center in Seattle, and colleagues studied mice that had been bred to lack a copy of the p53 gene, which encodes for alpha-catenin in the stem cells of hair follicles. The mice subsequently developed squamous cell carcinoma, indicating that alpha-catenin functions as a tumor suppressor. In addition, the alpha-catenin-mutant cells exhibited a hallmark characteristic of cancer cells by dividing continuously even in a very crowded Petri dish.

Further study by the scientists revealed that alpha-catenin controls the activity of another protein, Yap1, which can cause cancer if activated—making Yap1 a likely strong target in the treatment of squamous cell carcinoma.

“We found an inverse correlation between [alpha-catenin] abundance and Yap1 activation in human squamous cell carcinoma tumors,” affirmed the investigators in Science Signaling (2011;4[174]:ra33). “These findings identify [alpha-catenin] as a tumor suppressor that inhibits Yap1 activity and sequesters it in the cytoplasm.”

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs